×
Home Companies Industry Politics Money Opinion LoungeMultimedia Science Education Sports TechnologyConsumerSpecialsMint on Sunday
×

Lupin gets US nod for oral antibiotic, shares up

Lupin gets US nod for oral antibiotic, shares up
Comment E-mail Print Share
First Published: Fri, Dec 02 2011. 11 55 AM IST

A file photo of tablets
A file photo of tablets
Updated: Fri, Dec 02 2011. 11 55 AM IST
Mumbai: Indian drugmaker Lupin will sell the generic version of oral antibiotic Solodyn in the United States (US) after it received regulatory nod for the $750-million-a-year drug, it said on Friday.
Solodyn, made by US-based Medicis Pharmaceutical Corp, is used to treat pimples and red bumps.
A file photo of tablets
Lupin had settled a litigation with Medicis over the drug in July paving way for the US launch of the copy-cat version.
The settlement allowed Lupin to sell the antibiotic November onwards and also sell the same drug with different strengths from 2018 and 2019 onwards.
The current approval is for 45 mg, 55 mg, 90 mg and 135 mg dosage strengths, it said.
Lupin and Medicis also share a licensing pact to develop multiple therapeutic compounds using the Indian company’s formulation technologies.
At 11:40 am, shares of Lupin, which have lost 9% in value in last year, were trading at Rs 467.10, up 0.34% in a choppy Mumbai market.
Comment E-mail Print Share
First Published: Fri, Dec 02 2011. 11 55 AM IST
More Topics: Lupin | Drugs | Pharmaceutical | Antibiotic | Medicis |